Table 6.
HBV reactivation in HBsAg-negative patients treated for lymphoma and solid tumors
| Types | Prophylactic nucleos(t)ide analogs | Total patients (n) | Incidence [n, (%)] | Authors (year) [references] |
|---|---|---|---|---|
| Lymphoma (without rituximab-based regimens) | NA | 72 | 10 (14%) | Lok et al. (1991) [80] |
| Lymphoma (with rituximab-based regimens) | NA | 39 | 7 (17.9%) | Huang et al. (2013) [93] |
| Hematologic malignancy (with rituximab-based regimens) | NA | 28 | 3 (10.7%) | Buti et al. (2014) [94] |
| Lymphoma (with rituximab-based regimens) | NA | 578 | 36 (6.3%) | Mozessohn et al. (2015) [92] |
| Solid cancer | NA | 27 | 2 (7.4%) | Hagiwara et al. (2012) [98]. |
| Solid cancer | NA | 321 | 1 (0.3%) | Kim et al. (2014) [97] |
NA not applicable